The IKEA Foundation Pledges More Than €11 Million in Emergency Humanitarian Aid for Sudan
The IKEA Foundation has donated €5 million to Médecins Sans Frontières - Doctors Without Borders (MSF) to provide urgent medical care and supplies to people affected by the recent fighting in Sudan. It has also donated €6.7 million to Better Shelter to deploy 3,000 units to meet the immediate shelter needs of people displaced by the deadly conflict.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005375/en/
Illustration of fighting in Khartoum, Sudan Copyright: MSF/Atsuhiko Ochiai Countries: Sudan Date taken / Date Recorded: 04 May, 2023 Caption / Description: Aerial view captures the fighting and violence that erupted in Khartoum, Sudan. (Photo: Business Wire)
Intense fighting broke out in Khartoum, Sudan on 15 April and has since spread to other parts of the country. Local hospitals have been overwhelmed as people arrive with serious injuries caused by gunshots, explosions and airstrikes. The country’s health system, which has been struggling for decades, is facing a huge increase in needs and a shortage of supplies.
Within Sudan, many of those forced to flee are arriving in overcrowded urban areas already hosting internally displaced people. Sudan is also hosting more than one million refugees who have fled violence in neighbouring countries. This is placing immense strain on overstretched resources and exposing vulnerable people to risks such as evictions, family separation and gender-based violence.
Per Heggenes, CEO of the IKEA Foundation, said: “The violence in Sudan is a devastating human tragedy. It is our responsibility to alleviate the suffering of those caught in the crossfire. We strongly urge other funders to join us in delivering life-saving humanitarian assistance to Sudan. Let’s come together and make a tangible difference in the lives of those devastated by the conflict”
Urgent life-saving care by MSF
The IKEA Foundation’s donation will help MSF provide life-saving care both through medical interventions and by distributing supplies. It will also contribute to supporting MSF's activities across 10 states in Sudan. MSF teams have been treating war wounded, providing healthcare services and supplies, and water and sanitation.
Stephen Cornish – Director General – Médecins Sans Frontières (MSF) – Geneva Operational Centre said: “As the conflict in Sudan spirals into its second month and humanitarian needs outstrip response capacity, IKEA Foundation’s backing of our medical work across the country marks a collective resolution to take all possible measures to support those caught in the violence.
“The contribution is a testament to the determination and professionalism of our teams on the ground, who despite the many challenges and obstacles remain committed to extending life-saving healthcare. We are deeply thankful for the steadfast support of the IKEA Foundation. Today’s donation of €5 million will go a long way in helping us to provide humanitarian and medical aid to those most affected by the ongoing crisis.”
Immediate shelter needs by Better Shelter
An estimated 1.4 million Sudanese people have been displaced by this conflict already. This includes people fleeing internally and those crossing borders into neighbouring countries, including Chad and Ethiopia. Food, shelter, and protection services are among people’s urgent needs. To meet the immediate need for shelter as expressed by UNHCR, the UN Refugee Agency, Better Shelter will deploy 3,000 units immediately to neighbouring countries.
Johan Mast, Acting Manager Director, Better Shelter, said: “The current situation in Sudan is alarming. Millions of people are experiencing insecurity, food and water scarcity, and various challenges that require urgent attention. We are very grateful for the IKEA Foundation stepping in to assist and pleased to offer shelter to 15,000 individuals affected by the crisis. Shelter is a fundamental human need that provides physical protection and helps with emotional healing and recovery from the traumatic experiences they have endured.”
About the IKEA Foundation
The IKEA Foundation is a strategic philanthropy that focuses its grant making efforts on tackling the two biggest threats to children’s futures: poverty and climate change. It currently grants more than €200 million per year to help improve family incomes and quality of life while protecting the planet from climate change. Since 2009, the IKEA Foundation has granted more than €1.8 billion to create a better future for children and their families.
In 2021 the Board of the IKEA Foundation decided to make an additional €1 billion available over the next five years to accelerate the reduction of Greenhouse Gas emissions.
When an emergency strikes, time is of the essence. To provide the most efficient response, the IKEA Foundation provides extraordinary emergency funding to a select few partner organisations, who work mainly in Africa, Asia and the Middle East. In 2023 we have provided more than €31 Million in emergency funding.
About Médecins Sans Frontières
Médecins Sans Frontières (MSF) translates to Doctors without Borders, is a non-profit, self-governed, member-based organisation. MSF provides medical assistance to people affected by conflict, epidemics, disasters, or exclusion from healthcare. MSF teams are made up of tens of thousands of health professionals, logistic and administrative staff. Their actions are guided by medical ethics and the principles of impartiality, independence and neutrality.
Since 1978, as a first-hand witness and responder to the dire needs of the Sudanese people, MSF has mobilised teams across 12 states, implemented around 20 projects from primary and secondary healthcare, mobile clinics, nutrition, reproductive and mental healthcare to vaccination, health promotion, and water and sanitation.
About Better Shelter
Better Shelter is a humanitarian non-profit organisation based in Sweden. It started developing temporary shelters more than ten years ago, with a big mission dedicated to sheltering displaced persons with safety, dignity and hope on their path towards a more stable life in a permanent home of their own. While its work has grown in scale, the small team continues to support partners and deliver shelters internationally from warehouses in Poland, Türkiye, and Panama.
Since 2015, Better Shelter has delivered more than 85,000 shelters to emergency, crisis, and development programs in over 80 countries. Better Shelter has impacted the lives of hundreds of thousands of displaced persons through collaborations with humanitarian NGOs and INGOs, UN bodies, philanthropic foundations, and academic institutions, including the UN Refugee Agency, UNHCR, the IKEA Foundation and the Aga Khan Agency for Habitat. www.bettershelter.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005375/en/
Contact information
Lotika Mehta, lotika.mehta@ikeafoundation.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom